Attitudes of Clinicians Following Large-Scale Pharmacogenomics Implementation
Published Date:Aug 11 2015
Source:Pharmacogenomics J. 16(4):393-398.
Pubmed Central ID:PMC4751074
Funding:K23 HD000001/HD/NICHD NIH HHS/United States
KL2 TR000446/TR/NCATS NIH HHS/United States
U01 HG006378/HG/NHGRI NIH HHS/United States
U01 HG007253/HG/NHGRI NIH HHS/United States
U01 HG008672/HG/NHGRI NIH HHS/United States
U01 HL105198/HL/NHLBI NIH HHS/United States
U01 HL122904/HL/NHLBI NIH HHS/United States
U47 CI000824/CI/NCPDCID CDC HHS/United States
UL1 TR000445/TR/NCATS NIH HHS/United States
Description:Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients' response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug-genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.
application/octet-stream image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg
You May Also Like: